Methods and compositions for the treatment of melanoma

• US 10,864,259 B2
• Filed: 11/08/2018
• Issued: 12/15/2020
• Est. Priority Date: 08/03/2017
• Status: Active Grant

• Current Assignee: HTYR Acquisition LLC
• Original Assignee: Taiga Biotechnologies, Inc.
• Inventors: Refaeli, Yosef, Turner, Brian C., Bird, Gregory Alan
• Primary Examiner(s): Xiao, Yan
• Application Number:
  US16/184,086
• Publication Number:
  US 20190060434A1
• Time in Patent Office: 768 Days
• Field of Search: 424 9371
• CPC Class Codes: A61K 2039/515 Animal cells
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/57 Skin; melanoma
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001152 Transcription factors, e.g. SOX or c-MYC
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/464452 Transcription factors, e.g. SOX or c-MYC
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: C12N 2501/606 c-Myc
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0638 Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Abstract

Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).

Claims

1. A composition comprising:

(a) a MYC fusion peptide, comprising (i) a protein transduction domain;

(ii) a MYC polypeptide sequence, wherein the MYC fusion peptide comprises SEQ ID NO;

1; and

(b) one or more primary immune cells from a donor subject that has a melanoma tumor, wherein the one or more primary immune cells are reactive against a melanoma-specific antigen.

2. The composition of claim 1, wherein the protein transduction domain sequence is a TAT protein transduction domain sequence.

3. The composition of claim 1, wherein the one or more immune cells comprises a T cell, a B cell, an NK cell, or any combination thereof.

4. The composition of claim 1, wherein the one or more immune cells comprises a tumor-infiltrating lymphocyte, T-cell receptor modified lymphocyte, or a chimeric antigen receptor modified lymphocyte.

5. The composition of claim 4, wherein the tumor-infiltrating lymphocyte has a CD8+CD25+ signature or a CD4+CD25+ signature.